Human embryonic stem cells have potential to treat retinal degeneration

Article

Regeneration of damaged retinal cells with the aid of stem cells may offer hope for the treatment of retinal degeneration conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR), according to a report published by the National Academy of Sciences (Volume 103).

Regeneration of damaged retinal cells with the aid of stem cells may offer hope for the treatment of retinal degeneration conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR), according to a report published by the National Academy of Sciences (Volume 103).

Deepak A. Lamba of the University of Washington, US and team used human stem cells successfully to treat diseased rodent retinas. The team cultivated human embryonic stem cells (hES) to become retinal progenitor cells, which differentiate primarily into inner retinal neurons (ganglion and amacrine cells), with functional glutamate receptors.

These retinal progenitors were able to integrate with a degenerated mouse retina, which then increased in the expression of photoreceptor-specific markers, including rods and cones.

The researchers concluded that hES cells can be selectively directed to develop into neural retinal cells. This may provide an option for the treatment of retinal degenerations; in vivo tests in humans are planned to begin within two to three years.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
© 2025 MJH Life Sciences

All rights reserved.